Pharmafile Logo

Patients and data tracking

Empowering Employees: Unleashing Potential for a Bright Future

We believe that true empowerment is not just giving a person a voice, but the freedom and ability to act.

Page & Page Health

- PMLiVE

FDA declines to approve Amneal Pharmaceuticals’ Parkinson’s disease treatment

The regulator said the safety for one of the drug's ingredients had not been adequately established

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

NIHR and MRC establish UK Rare Disease Research Platform with £14m investment

The platform brings together expertise from across the UK rare disease research system

- PMLiVE

Choosing capabilities

Why tomorrow’s business model must be more capable than today’s model

- PMLiVE

[Free Case Study Booklet] Accelerating Patient Recruitment in a global rare disease trial

See how Innovative Trials supported a Top 5 pharma to complete enrollment in a Phase 2 Lupus study

Innovative Trials

Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market

Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.

Inizio

- PMLiVE

Research Partnership launches Access CGT

Research Partnership’s specialist market access team have launched Access CGT, a new syndicated access and policy tracker providing surveillance of the cell and gene therapy space.Read more

Inizio

- PMLiVE

Innovation in Education Leads to Positive Outcomes at EAN 2023

The Medscape team recently returned from the 9th Annual Congress of the European Academy of Neurology (EAN) in Budapest, Hungary. Among the various highlights of the congress, the team showcased...

Medscape Education

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links